Hepatocellular carcinoma (HCC) represents the most prevalent malignancy in Egypt and globally. However, non-invasive diagnostic/prognostic biomarkers for early detection of HCC are still lacking.

Mursla Bio has revealed outcomes from the MEV01 clinical study of its ‘EvoLiver’ blood test for the surveillance of hepatocellular carcinoma ... in the US as a laboratory-developed test ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Dr. David M. Dudzinski: A 59-year-old man with a history of obesity, dyslipidemia, and hypertension was evaluated in the oncology clinic of this hospital because of hepatocellular carcinoma.

Mursla Bio, a Cambridge UK and Boston US leader in Extracellular Vesicle (EV) science, has received FDA approval for its lead ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma ... used tests to detect HBV infection.

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.